India · Delayed Price · Currency is INR Krsnaa Diagnostics Earnings Call Transcripts
Fiscal Year 2026
-
FY 2026 saw revenue of INR 7,728 million, EBITDA margin of 28%, and PAT of INR 1,014 million, with strong growth in retail and major PPP expansion in Rajasthan. Receivables improved, CapEx of INR 5,000 million planned, and EBITDA margins are expected to be maintained.
-
Q3 FY26 saw modest revenue growth of 4% year-over-year, with strong cash flow from government receivable recovery and resilient margins despite expansion costs. Retail diagnostics grew 8x, and the Rajasthan project is expected to drive significant revenue by FY27.
-
Q2 FY26 saw 11% revenue growth and 18% EBITDA growth, with margins expanding to 29%. Retail business surged 60% quarter-on-quarter, now 8% of revenue, and is expected to reach 15-20% next year. Receivables remain elevated but are targeted to improve.
-
Q1 FY 2026 saw 13% revenue growth, 19% EBITDA growth, and 15% PAT growth, with retail revenue rising to 6% of total. The Rajasthan PPP contract expands scale, with full rollout in 6-9 months and material revenues from FY 2027. Margins and working capital remain strong.
Fiscal Year 2025
-
FY 2025 saw 16% revenue growth, 34% EBITDA growth, and 37% net profit growth, with margins expanding and a strong retail push. Receivable days are expected to normalize, and the company targets continued double-digit growth and margin improvement in FY 2026.
-
Q3 FY25 saw 10% YoY revenue growth and 50% net profit growth, despite temporary project delays. Retail expansion and asset-light models are set to drive future growth, with management confident in achieving 25% annual revenue growth guidance.
-
Q2 FY2025 saw 20% revenue growth and 87% PAT growth, with strong expansion in new states and robust operational efficiency. Strategic investments and partnerships are set to drive further growth, with guidance reaffirmed for 25% revenue growth and sustainable margins.
-
Q1 FY25 saw 22% revenue growth and 39% EBITDA growth, with strong expansion in radiology and pathology segments. Retail and PPP projects are driving network growth, while the company remains net debt-free and targets 25%+ revenue growth for FY25.